Ana Paula Ferreira Nunes

Ana Paula Ferreira Nunes

Auto-generated profile, based on publicly available information

Ana Paula Ferreira Nunes

Department of Pathology, Federal University of Espírito Santo, Espírito Santo, Brazil

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2011 in Memórias do Instituto Oswaldo Cruz
Verified
Journal Article
Open access
PDF file
LSLívia Viganor da Silva
Lívia Viganor da Silva
MAManuela Tedesco Araújo
Manuela Tedesco Araújo
KSKátia Regina Netto dos Santos
Kátia Regina Netto dos Santos
ANAna Paula Ferreira Nunes
Ana Paula Ferreira Nunes
Methicillin-resistant Staphylococcus aureus (MRSA) and coagulase-negative Staphylococcus spp (CNS) are the most common pathogens that cause serious long term infections in patients. Despite the existence of new antimicrobial agents, such as linezolid, vancomycin (VAN) remains the standard therapy for the treatment of infections caused by these multidrug-resistant strains. However, the use of VAN has been associated with a high frequency of therapeutic failures in some clinical scenarios, mainly with decreasing concentration of VAN. This work aims to evaluate the synergic potential of VAN plus sulfamethoxazole/trimethoprim (SXT), VAN plus rifampin (RIF) and VAN plus imipenem (IPM) in sub-minimum inhibitory concentrations against 22 clinical strains of MRSA and CNS. The checkerboard method showed synergism of VAN/RIF and VAN/SXT against two and three of the 22 strains, respectively. The combination of VAN with IPM showed synergistic effects against 21 out of 22 strains by the E-test method. Four strains were analyzed by the time-kill curve method and synergistic activity was observed with VAN/SXT, VAN/RIF and especially VAN/IPM in sub-inhibitory concentrations. It would be interesting to determine if synergy occurs in vivo. Evidence of in vivo synergy could lead to a reduction of the standard VAN dosage or treatment time.

31 July 2020 in Brazilian Journal of Microbiology
Verified
Journal Article
Closed access
PDF file
RVRoberta F. Ventura
Roberta F. Ventura
AGAnna Clara M. Galdino
Anna Clara M. Galdino
LVLivia Viganor
Livia Viganor
RSRicardo P. Schuenck
Ricardo P. Schuenck
MDMichael Devereux
Michael Devereux
ANAna Paula F. Nunes
Ana Paula F. Nunes

12 April 2021 in Letters in Applied Microbiology
Verified
Journal Article
Open access
PDF file
IPIngrid V Peregrino
Ingrid V Peregrino
RVRoberta F Ventura
Roberta F Ventura
MBMirla Borghi
Mirla Borghi
RSRicardo Pinto Schuenck
Ricardo Pinto Schuenck
MDMichael Devereux
Michael Devereux
ANAna Paula F Nunes
Ana Paula F Nunes
Infections caused by KPC‐producing Klebsiella pneumoniae (Kp‐KPC) are associated with high mortality rates due to the increased number of resistant isolates and the scarcity of therapeutic options. This scenario reinforces the urgent need for new chemotherapeutics. Herein, we investigated the effects of 1,10‐phenanthroline‐5,6‐dione (phendione) and its metal‐based complexes, [Cu(phendione)3](ClO4)2.4H2O (Cu‐phendione) and [Ag(phendione)2]ClO4 (Ag‐phendione), both alone and also combined with carbapenems (meropenem–MEM, and imipenem–IPM), against 46 clonally distinct clinical strains of Kp‐KPC. All isolates were found to be multidrug‐resistant in accordance with their susceptibility patterns by disk diffusion method. Compounds geometric mean (GM)‐MIC and GM‐MBC values (μM), respectively, were: phendione, 42.06 and 71.27; Cu‐phendione, 9.88 and 13.75; and Ag‐phendione, 10.10 and 13.06. Higher synergism rates of MEM‐containing combinations were observed by the checkerboard assay, particularly with the two metal complexes. Moreover, drug combinations were able to re‐sensitize 87% of the phenotypically non‐susceptible strains. Time‐kill studies, with MEM plus Cu‐phendione or Ag‐phendione, indicated that combinations with 0.5×MIC of each agent produce synergistic effects after 9‐12h. The MEM plus Ag‐phendione eradicated about 106 CFU ml–1 of bacteria. These findings support the effectiveness of the re‐sensitizing combinatorial approach and provide evidence that phendione‐based compounds offer real promise in the fight against Kp‐KPC infections.

29 July 2017 in The Brazilian Journal of Infectious Diseases
Verified
Journal Article
Open access
GAGeraldo da Silva Alves
Geraldo da Silva Alves
MPMonalessa Fábia Pereira
Monalessa Fábia Pereira
LBLais de Lima Bride
Lais de Lima Bride
ANAna Paula Ferreira Nunes
Ana Paula Ferreira Nunes
RSRicardo Pinto Schuenck
Ricardo Pinto Schuenck
Vancomycin-resistant Enterococcus faecium (VREfm) has emerged as an important global nosocomial pathogen, and this trend is associated with the spread of high-risk clones. Here, we determined the genetic and phenotypic features of 93 VREfm isolates that were obtained from patients in 13 hospitals in Vitória, Espírito Santo, Brazil, during 2012-2013. All the isolates were vancomycin-resistant and harbored the vanA gene. Only 6 (6.5%) of the VREfm isolates showed the ability to form biofilm. The 93 isolates analyzed belong to a single pulsed-field gel electrophoresis lineage and presented six subtypes. MLST genotyping showed that all VREfm belonged to ST412 (the high-risk clone, hospital-adapted). The present study describes the dissemination of ST412 clone in the local hospitals. The clonal spread of these ST412 isolates in the area we analyzed as well as other hospitals in southeastern Brazil supports the importance of identifying and controlling the presence of these microorganisms in health care-related services.

1 January 2024 in Acta Ortopedica Brasileira
Verified
Journal Article
Open access
PDF file
JMJoão Guilherme Tavares Marchiori
João Guilherme Tavares Marchiori
ANAna Paula Ferreira Nunes
Ana Paula Ferreira Nunes
Open fractures are highly incident injuries closely related to the modern life, in which accidents caused by motor vehicles or other machines impart high energy to bone tissue. Individual morbidity is represented by the functional impairment resultant of infection, nonunion, or vicious healing. In terms of public health, there are huge costs involved with the treatment of these fractures, particularly with their complications. One of the critical issues in managing open fractures is the use of antibiotics (ATB), including decisions about which specific agents to administer, duration of use, and ideal timing of the first prophylactic dose. Although recent guidelines have recommended starting antibiotic prophylaxis as soon as possible, such a recommendation appears to stem from insufficient evidence. In light of this, we conducted a systematic review, including studies that addressed the impact of the time to first antibiotic and the risk of infectious outcomes. Fourteen studies were selected, of which only four found that the early initiation of treatment with antibiotics is able to prevent infection. All studies had important risks of bias. The results indicate that this question remains open, and further prospective and methodologically sound studies are necessary in order to guide practices and health policies related to this matter. Level of Evidence II; Therapeutic Studies Investigating the Results Level of Treatment.

30 March 2026 in Current Topics in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
GSGabriela Seabra
Gabriela Seabra
VCVictor Carregari
Victor Carregari
IMInglid Souza da Mata
Inglid Souza da Mata
DLDomingos Leite
Domingos Leite
ASAndre Souza dos Santos
Andre Souza dos Santos
ANAna Paula Ferreira Nunes
Ana Paula Ferreira Nunes
Introduction: Multidrug-resistant (MDR) Klebsiella pneumoniae infections are associated with high mortality, prolonged hospitalization, and limited treatment options, representing a global healthcare challenge. The coordination compounds [Ag(1,10-phenanthroline-5,6- dione)2]ClO4 (Ag-phendione) and [Cu(1,10-phenanthroline-5,6-dione)3(ClO4)2] (Cu-phendione) have previously demonstrated antimicrobial and antibiofilm activity against MDR Gram-negative bacilli. Methods: This study investigated their mechanisms of action by combining classical microbiology with shotgun proteomics. Minimum inhibitory and bactericidal concentrations (MIC/MBC), timekill assay, and antibiofilm effects were determined, while nanoESI-LC-MS/MS identified proteins modulated in MDR K. pneumoniae. Results: MIC values ranged from 3.125 mg/L to 12.5 mg/L for Ag-phendione and from 12.5 mg/L to 50 mg/L for Cu-phendione. Both compounds exhibited early antimicrobial effects ( ≤ 3 h), inhibited biofilm formation, and disrupted mature biofilms in a dose-dependent manner. Proteomic analysis revealed modulation of proteins related to NAD⁺ synthesis, carbohydrate metabolism (notably trehalose), DNA replication and repair, oxidoreductase activity, and plasmid partitioning. Discussion: The modulation of these proteins correlates with the observed antimicrobial and antibiofilm activity of the coordination compounds, suggesting potential targets for further validation. Interestingly, several proteins modulated by these compounds are also affected by classical antibiotics such as meropenem and colistin, suggesting partially convergent mechanisms involving central metabolism and redox homeostasis. Conclusion: Ag-phendione and Cu-phendione are promising candidates for the development of novel therapeutics against MDR K. pneumoniae. Future studies should validate key targets through genetic knockouts or enzyme activity assays to clarify the mechanisms underlying these effects.